Patients to benefit from updated skin tumour publications
26 October 2018
Healthcare professionals specialising in skin cancers, including melanoma, now have access to two publications with the most current information relating to skin tumour diagnosis and management. Both publications – the WHO Classification of Skin Tumours, 4th Edition, and Pathology of Melanocytic Tumours – are co-edited by Professor Richard Scolyer, Co-Medical Director of Melanoma Institute Australia (MIA), and will have a major impact on the diagnosis and management of melanoma and other skin tumours.
The WHO Classification of Skin Tumours, 4th Edition integrates diagnostic information and pathological features of skin tumours with the latest in molecular, genetic and epidemiological information. This edition of the WHO Skin Blue Book has substantially updated the classification of melanoma and is a breakthrough publication that every pathologist, dermatopathologist, dermatologist, oncologist and other health care professionals who deal with skin tumours should have.
A separate textbook Professor Scolyer has edited with other world authorities from the USA is Pathology of Melanocytic Tumours. Constituting a large percentage of everyday diagnostic practice, melanocytic pathology is a complex and challenging area with many difficult-to-diagnose lesions. This highly illustrated reference, written by three of the world’s leading dermatopathologists, provides authoritative guidance in the accurate diagnosis of even the most challenging pigmented skin tumours.
‘These publications will undoubtedly assist the care of patients with melanoma and other skin cancers world-wide,” Professor Scolyer said.
The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.
A re-cap of the wonderful, and often very creative, community fundraising initiatives over the April to June quarter.
Our patients who donate their tissue samples and records to our research are helping to make a difference to the lives of future melanoma patients.
MIA researchers have recently been awarded two competitive funding grants, which will help facilitate their ground-breaking work in melanoma research.
Melanoma survivor Matt Kean is doing a 1000km bike ride around the Riverina this October, to increase awareness of melanoma and raise funds for Amie St Clair Melanoma - MIA. There are many ways you can be part of this life-changing ride!
Celebrate the 10th anniversary of Amie St Clair Melanoma at the Annual Ball in Wagga Wagga!
Riverina patients gain access to potentially life saving immunotherapy treatment close to home.
MIA's Prof Scolyer has been appointed as an Officer (AO) of the Order of Australia.
In a breakthrough which could extend to the treatment of other cancers, a new immune checkpoint inhibitor has proven effective in helping save the lives of advanced melanoma patients.
Whilst our research and clinical teams are trialling new treatments to save lives, it is our nurses who are on the front line providing care and support.
The easing of COVID restrictions has meant the return of community events, and we recognise the generous support of our community fundraisers.
Melanoma patients and their carers are being urged to participate in a ground-breaking survey which will shape the future of melanoma treatment, research, support and funding in Australia.
We have been buoyed by the wonderful support for our Melanoma March campaign, and our mission to cover Australia in footprints continues into April!
There was a wonderful feeling of community support amongst the melanoma patients, families and friends at the WA Melanoma Community Form.
The Price family has decided to share their story to inspire Australians to support research into new melanoma treatments.
New research has provided evidence in favour of a structured skin surveillance program for high-risk melanoma patients.
Melanoma research saved Bert's life at 101 and now he wants to give back.
A new MIA online risk calculator for clinicians can determine the likelihood of thin melanoma spreading.